Suppr超能文献

可溶性供体MHC I类抗原在体内外均可抑制免疫致敏。

Soluble donor MHC class I antigen inhibits immunologic priming in vitro and in vivo.

作者信息

Geissler E K, Scherer M N, Graeb C

机构信息

University of South Alabama, Department of Medical Technology, Mobile 36604-3273, USA.

出版信息

Transpl Int. 1998;11 Suppl 1:S357-60. doi: 10.1007/s001470050497.

Abstract

Previous studies suggest liver transplants can protect other transplanted organs. This effect may be mediated by hepatocytes secreting large amounts of soluble MHC class I antigen. Here our aim was to determine whether immunologic priming by membrane-bound alloantigen could be inhibited by allospecific antigen produced in a secreted form. Cultured Lewis (RT1.A1) hepatocytes were transfected with plasmids encoding either a membrane-bound or secreted form of the alloantigen, RT1.Aa. Cytotoxic T-lymphocyte (CTL) precursor assays were performed on Lewis splenocytes cultured with transfected hepatocytes, or hepatocytes were injected into the portal vein of prospective Lewis recipients of an ACI (RT1.Aa) liver allograft. Results showed CTL priming by membrane-bound RT1.Aa was inhibited in vitro by soluble RT1.Aa. Similarly, acceleration of ACI allograft rejection induced by membrane-bound antigen was abrogated following co-injection of hepatocytes secreting donor alloantigen. In conclusion, production of soluble donor alloantigen by liver transplants may provide protection against the alloimmune response.

摘要

先前的研究表明,肝移植可以保护其他移植器官。这种效应可能是由肝细胞分泌大量可溶性MHC I类抗原介导的。在这里,我们的目的是确定分泌形式产生的同种特异性抗原是否能够抑制膜结合同种异体抗原引发的免疫致敏。用编码膜结合或分泌形式同种异体抗原RT1.Aa的质粒转染培养的Lewis(RT1.A1)肝细胞。对与转染肝细胞共培养的Lewis脾细胞进行细胞毒性T淋巴细胞(CTL)前体细胞分析,或将肝细胞注入接受ACI(RT1.Aa)肝移植的Lewis受体的门静脉。结果显示,可溶性RT1.Aa在体外抑制了膜结合RT1.Aa引发的CTL致敏。同样,在共同注射分泌供体同种异体抗原的肝细胞后,由膜结合抗原诱导的ACI同种异体移植排斥反应加速现象被消除。总之,肝移植产生可溶性供体同种异体抗原可能提供针对同种免疫反应的保护作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验